Principal Financial Group Inc. Acquires 23,682 Shares of bluebird bio, Inc. (BLUE)

Principal Financial Group Inc. raised its holdings in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 52.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,185 shares of the biotechnology company’s stock after purchasing an additional 23,682 shares during the quarter. Principal Financial Group Inc. owned 0.15% of bluebird bio worth $9,503,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Hanseatic Management Services Inc. boosted its holdings in bluebird bio by 0.3% during the 2nd quarter. Hanseatic Management Services Inc. now owns 10,436 shares of the biotechnology company’s stock worth $1,096,000 after acquiring an additional 27 shares during the last quarter. Teacher Retirement System of Texas boosted its holdings in bluebird bio by 1.7% during the 2nd quarter. Teacher Retirement System of Texas now owns 3,250 shares of the biotechnology company’s stock worth $341,000 after acquiring an additional 53 shares during the last quarter. Cornerstone Capital Management Holdings LLC. boosted its holdings in bluebird bio by 0.8% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 17,955 shares of the biotechnology company’s stock worth $1,885,000 after acquiring an additional 140 shares during the last quarter. Prudential Financial Inc. boosted its holdings in bluebird bio by 4.0% during the 2nd quarter. Prudential Financial Inc. now owns 3,882 shares of the biotechnology company’s stock worth $408,000 after acquiring an additional 150 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in bluebird bio by 0.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,433 shares of the biotechnology company’s stock worth $3,302,000 after acquiring an additional 151 shares during the last quarter.

A number of equities analysts have issued reports on BLUE shares. Goldman Sachs Group reaffirmed a “buy” rating and set a $186.00 price objective on shares of bluebird bio in a report on Friday, October 6th. Jefferies Group reaffirmed a “buy” rating and set a $88.00 price objective on shares of bluebird bio in a report on Friday, August 11th. Maxim Group reaffirmed a “buy” rating and set a $170.00 price objective (up from $100.00) on shares of bluebird bio in a report on Monday, October 9th. BMO Capital Markets lifted their price objective on shares of bluebird bio from $134.00 to $162.00 and gave the stock a “buy” rating in a report on Monday, October 30th. Finally, BTIG Research raised shares of bluebird bio from a “neutral” rating to a “buy” rating and set a $177.00 price objective on the stock in a report on Thursday, November 2nd. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $134.35.

In other bluebird bio news, insider Jeffrey T. Walsh sold 4,900 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $125.73, for a total transaction of $616,077.00. Following the sale, the insider now directly owns 32,205 shares of the company’s stock, valued at $4,049,134.65. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Jeffrey T. Walsh sold 35,000 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $151.38, for a total transaction of $5,298,300.00. Following the sale, the insider now directly owns 62,305 shares in the company, valued at $9,431,730.90. The disclosure for this sale can be found here. Insiders sold a total of 106,918 shares of company stock worth $15,181,462 over the last three months. 3.90% of the stock is owned by insiders.

bluebird bio, Inc. (BLUE) opened at $162.30 on Tuesday. bluebird bio, Inc. has a fifty-two week low of $60.95 and a fifty-two week high of $174.65.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.05). The company had revenue of $7.71 million during the quarter, compared to analysts’ expectations of $8.47 million. bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. bluebird bio’s quarterly revenue was up 397.4% compared to the same quarter last year. During the same period last year, the firm posted ($2.07) earnings per share. equities analysts anticipate that bluebird bio, Inc. will post -6.68 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/12/05/principal-financial-group-inc-acquires-23682-shares-of-bluebird-bio-inc-blue.html.

bluebird bio Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply